Fortis to sell Dubai pathology business
Advertisement
In order to focus on growth in the India market, under its diagnostics business chain SRL, Fortis Hospital’s international market strategy has taken a backseat with the hospital now reported to shut down its pathology business in Dubai.
Currently Fortis is evaluating various proposals for the sale of its pathology business in Dubai, as confirmed by vccircle.com.
The report in the vccircle also points out the fact that Fortis is now focused to expand its business in India, after having being designated as one of the few Indian companies with a strong international market focus earlier. The market strategy however, is now reversed with more and more funds being invested in the Indian diagnostics business.
Fortis is reported to have earlier sold off its stake in Singapore based healthcare services unit RadLink-Asia Pte Ltd and its subsidiaries to Fullerton Healthcare Group for S$111 million (approximately $83.5 million or Rs 530 crore).
Earlier in 2010, Fortis promoters had also locked themselves into a takeover battle with Khazanah for Singapore's Parkway. They had later pulled out from the battle and sold their own stake to Khazanah.
Currently Fortis is evaluating various proposals for the sale of its pathology business in Dubai, as confirmed by vccircle.com.
The report in the vccircle also points out the fact that Fortis is now focused to expand its business in India, after having being designated as one of the few Indian companies with a strong international market focus earlier. The market strategy however, is now reversed with more and more funds being invested in the Indian diagnostics business.
Fortis is reported to have earlier sold off its stake in Singapore based healthcare services unit RadLink-Asia Pte Ltd and its subsidiaries to Fullerton Healthcare Group for S$111 million (approximately $83.5 million or Rs 530 crore).
Earlier in 2010, Fortis promoters had also locked themselves into a takeover battle with Khazanah for Singapore's Parkway. They had later pulled out from the battle and sold their own stake to Khazanah.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.